Tremblay Alain, McFadden Seamus, Bonifazi Martina, Luzzi Valentina, Kemp Samuel V, Gasparini Stefano, Chee Alex, MacEachern Paul, Dumoulin Elaine, Hergott Christopher A, Shah Pallav L
Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria "Ospedali Riuniti," Ancona, Italy.
J Bronchology Interv Pulmonol. 2018 Jul;25(3):218-223. doi: 10.1097/LBR.0000000000000500.
Endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration is a well-established first-line minimally invasive modality for mediastinal lymph node sampling. Although results are excellent overall, the technique underperforms in certain situations. We aimed to describe our results using a new 19-G EBUS-guided transbronchial needle aspiration device to determine safety and feasibility of this approach.
We completed a retrospective chart review of all cases performed to the time of data analysis at each of 3 study sites.
A total of 165 procedures were performed with a total of 297 individual lymph nodes or lesions sampled with the 19-G device by 10 bronchoscopists. Relatively large targets were selected for sampling with the device (mean lymph node size: 20.4 mm; lung lesions: 33.5 mm). A specific diagnosis was obtained in 77.3% of cases with an additional 13.6% of cases with benign lymphocytes, for a procedural adequacy rate of 90.9%. Procedure sample adequacy was 88.6% in suspected malignant cases, 91.0% in suspected sarcoidosis/lymphadenopathy cases, and 85.7% of cases with suspected lymphoma. On a per-node basis, a specific diagnosis was noted in 191/280 (68.2%) of samples, with an additional 61 showing benign lymphocytes for a per-node sample adequacy rate of 90%. One case (0.6%) of intraprocedure bleeding was noted.
A new flexible 19-G EBUS needle was successfully and safely applied in a large patient cohort for sampling of lung and enlarged mediastinal lesions with high diagnostic rates across clinical indications.
支气管内超声(EBUS)引导下经支气管针吸活检术是一种成熟的用于纵隔淋巴结采样的一线微创方法。尽管总体结果良好,但该技术在某些情况下表现不佳。我们旨在描述使用新型19G EBUS引导下经支气管针吸活检装置的结果,以确定该方法的安全性和可行性。
我们对3个研究地点各自在数据分析时完成的所有病例进行了回顾性病历审查。
10名支气管镜检查医师使用19G装置共进行了165例手术,共采集了297个单个淋巴结或病变样本。该装置选择的采样目标相对较大(平均淋巴结大小:20.4毫米;肺部病变:33.5毫米)。77.3%的病例获得了明确诊断,另有13.6%的病例为良性淋巴细胞,手术充足率为90.9%。疑似恶性病例的手术样本充足率为88.6%,疑似结节病/淋巴结病病例为91.0%,疑似淋巴瘤病例为85.7%。按每个淋巴结计算,191/280(68.2%)的样本获得了明确诊断,另有61个样本显示为良性淋巴细胞,每个淋巴结样本充足率为90%。记录到1例(0.6%)术中出血。
一种新型的柔性19G EBUS针已成功且安全地应用于大量患者队列,用于肺部和肿大纵隔病变的采样,在各种临床指征下均具有较高的诊断率。